BACKGROUND: The prevalence and spectrum of predisposing mutations among children and adolescents with cancer are largely unknown. Knowledge of such mutations may improve the understanding of tumorigenesis, direct patient care, and enable genetic counseling of patients and families. METHODS: In 1120 patients younger than 20 years of age, we sequenced the whole genomes (in 595 patients), whole exomes (in 456), or both (in 69). We analyzed the DNA sequences of 565 genes, including 60 that have been associated with autosomal dominant cancer-predisposition syndromes, for the presence of germline mutations. The pathogenicity of the mutations was determined by a panel of medical experts with the use of cancer-specific and locus-specific genetic databases, the medical literature, computational predictions, and second hits identified in the tumor genome. The same approach was used to analyze data from 966 persons who did not have known cancer in the 1000 Genomes Project, and a similar approach was used to analyze data from an autism study (from 515 persons with autism and 208 persons without autism). RESULTS: Mutations that were deemed to be pathogenic or probably pathogenic were identified in 95 patients with cancer (8.5%), as compared with 1.1% of the persons in the 1000 Genomes Project and 0.6% of the participants in the autism study. The most commonly mutated genes in the affected patients were TP53 (in 50 patients), APC (in 6), BRCA2 (in 6), NF1 (in 4), PMS2 (in 4), RB1 (in 3), and RUNX1 (in 3). A total of 18 additional patients had protein-truncating mutations in tumor-suppressor genes. Of the 58 patients with a predisposing mutation and available information on family history, 23 (40%) had a family history of cancer. CONCLUSIONS: Germline mutations in cancer-predisposing genes were identified in 8.5% of the children and adolescents with cancer. Family history did not predict the presence of an underlying predisposition syndrome in most patients. (Funded by the American Lebanese Syrian Associated Charities and the National Cancer Institute.).
BACKGROUND: The prevalence and spectrum of predisposing mutations among children and adolescents with cancer are largely unknown. Knowledge of such mutations may improve the understanding of tumorigenesis, direct patient care, and enable genetic counseling of patients and families. METHODS: In 1120 patients younger than 20 years of age, we sequenced the whole genomes (in 595 patients), whole exomes (in 456), or both (in 69). We analyzed the DNA sequences of 565 genes, including 60 that have been associated with autosomal dominant cancer-predisposition syndromes, for the presence of germline mutations. The pathogenicity of the mutations was determined by a panel of medical experts with the use of cancer-specific and locus-specific genetic databases, the medical literature, computational predictions, and second hits identified in the tumor genome. The same approach was used to analyze data from 966 persons who did not have known cancer in the 1000 Genomes Project, and a similar approach was used to analyze data from an autism study (from 515 persons with autism and 208 persons without autism). RESULTS: Mutations that were deemed to be pathogenic or probably pathogenic were identified in 95 patients with cancer (8.5%), as compared with 1.1% of the persons in the 1000 Genomes Project and 0.6% of the participants in the autism study. The most commonly mutated genes in the affected patients were TP53 (in 50 patients), APC (in 6), BRCA2 (in 6), NF1 (in 4), PMS2 (in 4), RB1 (in 3), and RUNX1 (in 3). A total of 18 additional patients had protein-truncating mutations in tumor-suppressor genes. Of the 58 patients with a predisposing mutation and available information on family history, 23 (40%) had a family history of cancer. CONCLUSIONS: Germline mutations in cancer-predisposing genes were identified in 8.5% of the children and adolescents with cancer. Family history did not predict the presence of an underlying predisposition syndrome in most patients. (Funded by the American Lebanese Syrian Associated Charities and the National Cancer Institute.).
Authors: Xiang Chen; Pankaj Gupta; Jianmin Wang; Joy Nakitandwe; Kathryn Roberts; James D Dalton; Matthew Parker; Samir Patel; Linda Holmfeldt; Debbie Payne; John Easton; Jing Ma; Michael Rusch; Gang Wu; Aman Patel; Suzanne J Baker; Michael A Dyer; Sheila Shurtleff; Stephen Espy; Stanley Pounds; James R Downing; David W Ellison; Charles G Mullighan; Jinghui Zhang Journal: Nat Methods Date: 2015-05-04 Impact factor: 28.547
Authors: Michael N Edmonson; Jinghui Zhang; Chunhua Yan; Richard P Finney; Daoud M Meerzaman; Kenneth H Buetow Journal: Bioinformatics Date: 2011-01-28 Impact factor: 6.937
Authors: Sarah L Sawyer; Lei Tian; Marketta Kähkönen; Jeremy Schwartzentruber; Martin Kircher; Jacek Majewski; David A Dyment; A Micheil Innes; Kym M Boycott; Lisa A Moreau; Jukka S Moilanen; Roger A Greenberg Journal: Cancer Discov Date: 2014-12-03 Impact factor: 39.397
Authors: Ana Osorio; Miguel de la Hoya; Raquel Rodríguez-López; Angel Martínez-Ramírez; Alicia Cazorla; Juan José Granizo; Manel Esteller; Carmen Rivas; Trinidad Caldés; Javier Benítez Journal: Int J Cancer Date: 2002-05-10 Impact factor: 7.396
Authors: Amber J Willems; Sarah-Jane Dawson; Hema Samaratunga; Alessandro De Luca; Yoland C Antill; John L Hopper; Heather J Thorne Journal: Clin Cancer Res Date: 2008-04-29 Impact factor: 12.531
Authors: Amy M Dworkin; Andrew D Spearman; Stephanie Y Tseng; Kevin Sweet; Amanda Ewart Toland Journal: Fam Cancer Date: 2009-04-02 Impact factor: 2.375
Authors: Chenan Zhang; Quinn T Ostrom; Helen M Hansen; Julio Gonzalez-Maya; Donglei Hu; Elad Ziv; Libby Morimoto; Adam J de Smith; Ivo S Muskens; Cassie N Kline; Zalman Vaksman; Hakon Hakonarson; Sharon J Diskin; Carol Kruchko; Jill S Barnholtz-Sloan; Vijay Ramaswamy; Francis Ali-Osman; Melissa L Bondy; Michael D Taylor; Catherine Metayer; Joseph L Wiemels; Kyle M Walsh Journal: Neuro Oncol Date: 2020-11-26 Impact factor: 12.300
Authors: Chenan Zhang; Joseph L Wiemels; Helen M Hansen; Julio Gonzalez-Maya; Alyson A Endicott; Adam J de Smith; Ivan V Smirnov; John S Witte; Libby M Morimoto; Catherine Metayer; Kyle M Walsh Journal: Cancer Epidemiol Biomarkers Prev Date: 2018-07-23 Impact factor: 4.254
Authors: Alisa M Goldstein; Elizabeth M Gillanders; Melissa Rotunno; Rolando Barajas; Mindy Clyne; Elise Hoover; Naoko I Simonds; Tram Kim Lam; Leah E Mechanic Journal: Cancer Epidemiol Biomarkers Prev Date: 2020-05-28 Impact factor: 4.254
Authors: Petr Triska; Kristiyana Kaneva; Daria Merkurjev; Noor Sohail; Marni J Falk; Timothy J Triche; Jaclyn A Biegel; Xiaowu Gai Journal: Cancer Res Date: 2019-02-01 Impact factor: 12.701